Iterum Therapeutics to Present Data at ASM Microbe 2023
12. Juni 2023 18:23 ET
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports First Quarter 2023 Financial Results
12. Mai 2023 07:00 ET
|
Iterum Therapeutics PLC
--Registration Trial for uUTI Ongoing and On Track-- --Cash Runway until Mid-2024-- DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum),...
Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials
20. April 2023 17:00 ET
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, April 20, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
16. März 2023 07:00 ET
|
Iterum Therapeutics PLC
--Registration Trial for uUTI Ongoing and On Track----Cash Runway until Mid-2024-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 16, 2023 (GLOBE...
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
09. März 2023 17:00 ET
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Employment Inducement Grant
11. Januar 2023 18:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage pharmaceutical company focused on developing next...
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
15. Dezember 2022 08:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next...
Iterum Therapeutics Reports Third Quarter 2022 Financial Results
10. November 2022 07:00 ET
|
Iterum Therapeutics plc
--Patient Enrollment in Registration Trial for uUTI Underway-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM)...
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022
03. November 2022 08:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
20. Oktober 2022 07:30 ET
|
Iterum Therapeutics plc
-- NDA resubmission expected in Second Half of 2024, if successful-- --Oral sulopenem, if approved, could be the first antibiotic approved for uncomplicated urinary tract infections in over 25...